Key terms
About ABEO
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABEO news
Today
4:27pm ET
Abeona Therapeutics: Key Director Elections and Share Resolutions Passed
Yesterday
7:12am ET
Abeona CRL ‘a punch to the gut,’ but not end of the road, says Cantor Fitzgerald
Apr 22
4:36pm ET
Abeona Therapeutics trading resumes
Apr 22
4:12pm ET
Abeona receives FDA CRL on Pz-cel for additional CMC information
Apr 22
4:01pm ET
Abeona Therapeutics trading halted, news pending
Apr 01
8:31am ET
Abeona Therapeutics announces employee inducement grants
Mar 18
7:34am ET
Abeona Therapeutics announces FDA completed PLI of its Ohio facility
Mar 18
7:34am ET
Abeona Therapeutics reports FY23 EPS ($2.53), consensus ($2.23)
Mar 05
7:34am ET
Abeona Therapeutics announces new employee inducement grants
Feb 01
7:37am ET
Abeona Therapeutics announces progress update on Pz-cel BLA
ABEO Financials
Key terms
Ad Feedback
ABEO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABEO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range